Hong Kong-based life science investment firm Ally Bridge Group last Wednesday announced that it has led an over-subscribed US$65 million funding round in Pulmonx Corporation, a company that specializes in diagnostic and therapeutic pulmonary device technologies.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
